Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. Read More
Source link
Investor Unease Builds Entering War’s Fifth Week
(Bloomberg) — A record month for crude, stocks in or near correction territory, bonds under pressure and a growing sense that there are few tools to shield markets from an…







